Elite Pharmaceuticals, Inc
| Products & Pipeline | ||||
| Drug | Market Size | Status | Competitors | Marketed By |
| Adderall IR | 335 M | On Market | 14 | Elite |
| Adderall XR | 1.56 B | On Market | 9 | Elite |
| Dantrolene | 6.3 M | On Market | 2 | Elite |
| Isradipine | 5.5 M | On Market | 1 | Elite |
| Loxapine | 5 M | On Market | 2 | Elite |
| Phendimetrazine | 4.5 M | On Market | 4 | Elite |
| Trimipramine | 2 M | On Market | 1 | Elite |
| Naltrexone | 16 M | On Market | 5 | Tagi |
| Phentermine Capsules | 7.5 M | On Market | 6 | Tagi |
| Phentermine Tablets | 40 M | On Market | 8 | Tagi |
| Oxycodone IR | 400 M | On Market | 10 | Epic |
| Vigabatrin | 275 M | Approved - Launching 2nd half of 2023 | 15 | Pyros |
| Doxycycline | 85 M | Approved - Evaluating Market Opportunites | 9 | ---------- |
| Tylenol with Codeine | 45 M | Approved - On Hold (Opioid Product) | 4 | ---------- |
| Undisclosed Dopamine Agonist | 12 M | Filed with FDA 22 Dec 2022 | ---------- | ---------- |
| Undisclosed Antimetabolite | 42 M | Filed with FDA 20 Apr 2023 | ---------- | ---------- |
| Generic OxyContin | 517 M | Human Insufflation PK Study | ---------- | ---------- |
| Generic Concerta | 1.159 B | In Development | ---------- | ---------- |
| Generic Vyvanse | 2.53 B | In Development | ---------- | ---------- |
| SequestOx | 400 M | On Hold | ---------- | ---------- |
| Financials | ||||
| Fiscal Year | Revenue | Change | Net Income | Change |
| 2019 | 7,568,508 | (9,279,321) | ||
| 2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
| 2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
| 2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
| 2023 | 29 June 2023 | 29 June 2023 | ||
